drugset / Trial / NCT01850641
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.
Timeline
- Start
- 2013-04-29
- Primary completion
- 2013-12
- Completion
- 2013-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PA21 | Unknown | — | — |